Clinical Trial Update: Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluated whether lenalidomide enhances the response to the Hepatitis B vaccine in patients with plasma cell disorders. The study is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasma Cell Disorders

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Boston VA Research Institute, Inc. | Conditions: Plasma Cell Disorder | Phase 2 | Status: COMPLETED | Results posted: 2016-05-17